IN2012DN06631A - - Google Patents

Info

Publication number
IN2012DN06631A
IN2012DN06631A IN6631DEN2012A IN2012DN06631A IN 2012DN06631 A IN2012DN06631 A IN 2012DN06631A IN 6631DEN2012 A IN6631DEN2012 A IN 6631DEN2012A IN 2012DN06631 A IN2012DN06631 A IN 2012DN06631A
Authority
IN
India
Prior art keywords
yloxy
methyl
isoxazol
pyran
piperidin
Prior art date
Application number
Other languages
English (en)
Inventor
Hirohide Noguchi
Nobuaki Waizumi
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IN2012DN06631A publication Critical patent/IN2012DN06631A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN6631DEN2012 2010-02-16 2011-02-09 IN2012DN06631A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30492110P 2010-02-16 2010-02-16
PCT/IB2011/050548 WO2011101774A1 (fr) 2010-02-16 2011-02-09 (r)-4-((4-((4-(tétrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)méthyl) pipéridin-1-yl)méthyl)tétrahydro-2h-pyran-4-ole, agoniste partiel des récepteurs 5-ht4

Publications (1)

Publication Number Publication Date
IN2012DN06631A true IN2012DN06631A (fr) 2015-10-23

Family

ID=43904611

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6631DEN2012 IN2012DN06631A (fr) 2010-02-16 2011-02-09

Country Status (15)

Country Link
US (1) US20120041026A1 (fr)
EP (1) EP2536713A1 (fr)
JP (1) JP2013519722A (fr)
KR (1) KR20120123089A (fr)
CN (1) CN102762554A (fr)
AR (1) AR080172A1 (fr)
AU (1) AU2011216950A1 (fr)
CA (1) CA2788656A1 (fr)
IN (1) IN2012DN06631A (fr)
MX (1) MX2012008721A (fr)
SG (1) SG183111A1 (fr)
TW (1) TW201141856A (fr)
UY (1) UY33225A (fr)
WO (1) WO2011101774A1 (fr)
ZA (1) ZA201206469B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10583138B2 (en) 2012-07-12 2020-03-10 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
MX350024B (es) * 2011-05-18 2017-08-23 Raqualia Pharma Inc Formas polimorfas del ácido 4-{[4-({[4-(2,2,2-trifluoroetoxi)-1,2- benzisoxazol-3-il]oxi}metil)piperidin-1-il]metil}-tetrahidro-2h-p iran-4-carboxílico.
HK1208457A1 (en) * 2012-11-21 2016-03-04 拉夸里亚创药株式会社 Polymorph forms
US9790211B2 (en) 2013-03-20 2017-10-17 Suven Life Sciences Limited 5-amino-quinoline-8-carboxamide derivatives as 5-HT4 receptor agonists
KR101824154B1 (ko) 2013-12-16 2018-03-14 수벤 라이프 사이언시스 리미티드 5-ｈｔ４ 수용체 작용제로서 인다졸 화합물
EP3145926B1 (fr) * 2014-05-20 2019-07-03 RaQualia Pharma Inc. Sel de dérivé de benzisoxazole
SI3265459T1 (sl) 2015-02-13 2019-09-30 Suven Life Sciences Limited, Amidne spojine kot 5-HT4 receptor agonisti
CN117796401A (zh) * 2023-12-25 2024-04-02 江苏万隆化学有限公司 一种含2-羟基-6-氟苯甲酸甲酯中间体抗菌剂的制备工艺

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100224045B1 (ko) 1991-02-27 1999-10-15 슈테펜엘.네스비트 엔엠디에이(nmda) 길항제
US5750542A (en) * 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
NZ243065A (en) * 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
AU690529B2 (en) * 1992-11-23 1998-04-30 Hoechst Marion Roussel, Inc. Substituted 3-(aminoalkylamino)-1,2-benzisoxazoles and related compounds
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
JP4108123B2 (ja) 1995-09-29 2008-06-25 グラクソスミスクライン・ソシエタ・ペル・アチオニ Ｎｍｄａアンタゴニストとしてのテトラヒドロキノリン
IL126003A0 (en) 1996-04-10 1999-04-11 Hoechst Marion Roussel Inc Spiro [cyclopent [b] indole-piperidines] and n-[phenyl-hydrazon intermediates for their preparation both being acetyl cholinesterase and mao inhibitors
CA2252039C (fr) 1996-04-12 2002-12-24 Hoechst Marion Roussel, Inc. Derives d'isatine utilises comme inhibiteurs d'acetylcholinesterase et comme analgesiques
HUP9904167A3 (en) 1996-07-01 2000-07-28 Schering Corp 1,4-disubstituted piperazine and piperidine derivatives, their use and pharmaceutical compositions containing the same
CN1155574C (zh) 1996-08-15 2004-06-30 先灵公司 醚毒蕈碱性拮抗剂
DE69734594T2 (de) 1996-09-30 2006-07-06 Aventis Pharmaceuticals Inc. Nmda (n-methyl-d-aspartate) antagonists
CN1535682A (zh) 1998-09-30 2004-10-13 ����ҩƷ��ҵ��ʽ���� 改善膀胱排泄能力的药物
ATE380172T1 (de) 2001-01-26 2007-12-15 Btg Int Ltd Benzylaminanalogen
JP2005506292A (ja) 2001-03-08 2005-03-03 エモリー　ユニバーシティ ｐＨに依存するＮＭＤＡレセプターアンタゴニスト
US7259157B2 (en) 2001-04-03 2007-08-21 Merck & Co., Inc. N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists
SK287726B6 (en) 2001-07-24 2011-07-06 Richter Gedeon Vegyeszet Carboxylic acid amide derivatives, their preparation, pharmaceutical compositions containing them and process for preparing pharmaceutical compositions
EP1648882B1 (fr) 2003-06-04 2008-08-06 Merck & Co., Inc. 3-fluoro-piperidines en tant qu'antagonistes de nmda/nr2b
GB0316094D0 (en) 2003-07-09 2003-08-13 Neuropharma Sa Acetylcholinesterase dual inhibitors
LT2985039T (lt) * 2004-03-03 2018-11-12 Revance Therapeutics, Inc. Botulino toksinų vietinis taikymas ir jų įvedimas per odą
HU227119B1 (en) 2004-07-29 2010-07-28 Richter Gedeon Nyrt Indole and benzimidazole carboxylic acid amide derivatives and pharmaceutical compositions containing them
HU226977B1 (en) 2004-07-29 2010-04-28 Richter Gedeon Nyrt Kynurenic acid amide derivatives, pharmaceutical compositions containing them and process for producing them
HUP0401522A2 (en) 2004-07-29 2006-04-28 Richter Gedeon Vegyeszet New 4-benzylidene-piperidine derivatives, pharmaceutical compositions containing the same and process for their preparation
HUP0401523A3 (en) 2004-07-29 2007-05-02 Richter Gedeon Vegyeszet Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them
HU227000B1 (en) 2004-07-29 2010-04-28 Richter Gedeon Nyrt Nmda receptor antagonist benzoyl urea derivatives, and pharmaceutical compositions containing them
TW200621677A (en) 2004-09-21 2006-07-01 Astellas Pharma Inc Cyclic amine derivative or salt thereof
CA2582640A1 (fr) 2004-10-15 2006-04-20 Universidade Federal Do Rio De Janeiro-Ufrj Derives de piperidine, compositions pharmaceutiques les contenant et procedes pour les preparer
ES2523459T3 (es) * 2005-02-25 2014-11-26 Raqualia Pharma Inc Derivados de benzisoxazol
US20090124600A1 (en) 2005-04-19 2009-05-14 Layton Mark E N-Alkyl-Azacycloalkyl NMDA/NR2B Antagonists
JP2009503520A (ja) 2005-07-29 2009-01-29 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ ベータアミロイド受容体及びその使用
JP2009531323A (ja) 2006-03-20 2009-09-03 カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ アセチルコリンエステラーゼ阻害剤として有用な薬剤組成物
ES2288406B1 (es) 2006-04-20 2008-12-16 Universidad De Barcelona Compuestos inhibidores de acetilcolinesterasa para el tratamiento de la enfermedad de alzheimer.
JP2010513395A (ja) 2006-12-20 2010-04-30 ソルベイ・フアーマシユーチカルズ・ベー・ブイ カンナビノイド−ｃｂ１拮抗作用とアセチルコリンエステラーゼ阻害の組み合わせを示す化合物
US7605265B2 (en) 2007-01-22 2009-10-20 Biotechnology Research Corporation Ltd. Heterodimers and methods of using them
PL2345653T3 (pl) 2007-05-01 2013-05-31 Concert Pharmaceuticals Inc Związki morfianu
CN101730706B (zh) 2007-05-11 2015-04-15 生物科技研究有限公司 具有神经保护和增强记忆活性的受体拮抗剂
EA201070077A1 (ru) 2007-06-29 2010-08-30 Эмори Юниверсити Антагонисты nmda-рецепторов с нейропротективным действием
AP2010005217A0 (en) 2007-09-12 2010-04-30 Virginia Tech Intell Prop Insecticidal carbamates exhibiting species-selective inhibition of acetyl cholinesterase (ACHE)
GB2470495B (en) 2008-01-16 2012-12-26 Biotechnology Res Corp Ltd Oxazolidine derivatives as NMDA antagonists
EA014100B1 (ru) 2008-02-21 2010-08-30 Общество С Ограниченной Ответственностью "Валексфарм" Производные 2,4-диаминопиридина, фармацевтическая композиция, лекарственное средство на их основе для лечения или предупреждения заболеваний и нарушений, вызванных гиперактивацией nmda-рецепторов и/или в качестве стимуляторов когнитивных функций и способ лечения
CN101440061B (zh) 2008-04-08 2010-12-08 温州医学院 一类具有抑制乙酰胆碱酯酶活性的芳基吡啶酮类衍生物
WO2009129181A1 (fr) 2008-04-14 2009-10-22 Concert Pharmaceuticals Inc. Dérivés de dicarbamate de propanediol
MX2010012186A (es) 2008-05-09 2011-02-22 Univ Emory Antagonistas del receptor nmda para el tratamiento de transtornos neuropsiquitricos.

Also Published As

Publication number Publication date
US20120041026A1 (en) 2012-02-16
CA2788656A1 (fr) 2011-08-25
TW201141856A (en) 2011-12-01
ZA201206469B (en) 2013-05-29
AR080172A1 (es) 2012-03-21
UY33225A (es) 2011-09-30
MX2012008721A (es) 2012-08-17
WO2011101774A1 (fr) 2011-08-25
KR20120123089A (ko) 2012-11-07
CN102762554A (zh) 2012-10-31
SG183111A1 (en) 2012-09-27
EP2536713A1 (fr) 2012-12-26
JP2013519722A (ja) 2013-05-30
AU2011216950A1 (en) 2012-08-23

Similar Documents

Publication Publication Date Title
IN2012DN06631A (fr)
MX2009009428A (es) Analogos de ciclopamina heterociclicos y metodos de uso de los mismos.
MX2009009429A (es) Analogos de ciclopamina lactama y metodos de uso de los mismos.
AU2011367301A8 (en) Apparatus and method for controlling brightness in potable terminal
BR112012031620A2 (pt) atm acessível para deficiente físico
PL2438178T3 (pl) Mikroorganizmy do produkcji 1,4-butanodiolu i pokrewne sposoby
GB201306971D0 (en) Systems, devices, and/or methods for managing implantable devices
TN2009000185A1 (en) Progesterone receptor antagonists
UA102065C2 (en) Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
EP3825403A3 (fr) Procédés et compositions de modulation de l'expression de l'apolipoprotéine(a)
GB201118864D0 (en) Screen capture
MX362362B (es) Pilar dental para el soporte de protesis dentales y metodo de fabricacion del mismo.
PH12014500541A1 (en) Various control elements in a hybrid game
NZ603625A (en) A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
AU2011305525A8 (en) Modulators of the GPR119 receptor and the treatment of disorders related thereto
MY185134A (en) 6-substituted phenoxychroman carboxylic acis derivatives
TN2011000653A1 (en) Pharmaceutical compositions and solid forms
MY156946A (en) Composition for decreasing hardness of water
EP4494704A3 (fr) Utilisation de dérivés d'amide cyclique pour traiter des troubles du sommeil
AU335070S (en) Integrated winchhead
PH12014500538A1 (en) Methods and compositions for treating leukemia
PL401820A1 (pl) Uklad i sposób dezynfekcji i dezodoryzacji systemów gromadzenia odpadów wykorzystujace ozon
IN2014CN00834A (fr)
IN2014CN00817A (fr)
WO2009120381A3 (fr) Système de robinets et procédé de publicité